Investors Affected by Aardvark Therapeutics Lawsuit Seek Class Action Representation

Shareholder Alert: Join the Class Action Against Aardvark Therapeutics

Aardvark Therapeutics, Inc. (NASDAQ: AARD) is currently under fire as investors react to a significant drop in their stock value. Following the disclosure of troubling safety data related to their drug ARD-101, there has been a swift shift in Wall Street's perception of the company. Analysts have drastically reduced their price targets for AARD, prompting investors who have incurred losses to consider legal action and potentially file as lead plaintiffs in a class-action lawsuit.

Background of the Case

The lawsuit centers around allegations that Aardvark Therapeutics misrepresented the safety profile of their treatment, ARD-101. Initially marketed as an innovative therapy that remained largely in the digestive tract, the company's assertions have now been called into question following a series of unfortunate announcements.

On February 27, 2026, Aardvark announced a voluntary pause in their Phase 3 HERO clinical trial due to concerning cardiac observations at high therapeutic doses. This development led major financial firms to reassess their outlooks for the company, resulting in drastic reductions in stock price targets. Morgan Stanley, a notable player in the financial services sector, slashed its target from $29 to $7, marking an astonishing 75.9% decrease. Following this news, Aardvark's share price plummeted, causing serious financial distress for investors who had acquired shares at inflated values.

The Aftermath of Analyst Downgrades

The repercussions of the analysts’ downgrades swiftly impacted investor sentiment. By March 2, shares of Aardvark were trading at $5.47, down 56.2%. Furthermore, subsequent announcements from Aardvark have led to growing speculation regarding the future of their drug and the overall health of the company.

Investors are particularly alarmed by statements from other analysts, such as BTIG and Bank of America Securities, which have further lowered their price targets in light of the ongoing uncertainties surrounding the HERO trial. In total, Aardvark's stock saw a staggering drop of approximately 32.1%, or $2.16 per share, after the FDA imposed a full clinical hold on its investigational new drug application.

What Investors Should Do Now

For shareholders who purchased AARD securities between February 13, 2025, and May 14, 2026, there is an opportunity to seek legal recourse. Those affected are encouraged to gather relevant documents such as brokerage records to substantiate their claims. The deadline to apply for lead plaintiff designation in this class-action case is October 13, 2026.

Understanding Class Action Participation

Participation in this lawsuit doesn’t require immediate action; however, staying informed about the developments is crucial. Investors with documented losses during the class period may still be eligible for recovery, even if they have sold their shares. It's important to remember that legal representation in such cases is typically handled on a contingency basis, meaning there are generally no upfront costs for eligible participants.

Legal Expertise Behind the Case

The firm facilitating this legal action, Levi & Korsinsky LLP, has a strong history of championing shareholder rights. Known for their successes in complex securities litigation, they are well-equipped to navigate the challenges presented in this class action against Aardvark Therapeutics. Investors interested in pursuing this legal avenue can reach out for a no-obligation consultation to evaluate their potential claims.

Conclusion

As Aardvark navigates these turbulent waters, investors remain watchful of how the legal proceedings unfold. With major financial losses at stake, affected shareholders are urged to consider their options for participating in the class action lawsuit, underscoring the importance of transparency and accountability within the biotech sector.